IQVIA Holdings Inc

IQVIA Holdings Inc(IQV)股票分析

$271.040

+9.351 (+3.45%)收盤時

Loading chart…
最高
271.680
開盤
265.100
成交量加權均價
268.16
成交量
1.46M
市值
38.76B
最低
261.770
成交金額
390.73M
企業價值/稅息折舊攤銷前利潤(TTM)
16.28

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.

AI 分析 of IQVIA Holdings Inc (IQV)

買進

IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.

分析師評級(17)

-4.70% 下跌空間
買進
9 買進
8 持有
0 賣出
目前: 271.04
最低
215.00
平均
258.31
最高
290.00

BofA

2026-10-09

目標價

$305

買進

Mizuho

2026-10-07

目標價

$300

優於大盤

Barclays

2026-10-07

目標價

$300

增持

UBS

2026-09-30

目標價

$345

買進

RBC Capital

2026-09-29

目標價

$319

優於大盤

估值指標

IQVIA Holdings Inc(IQV)目前預期本益比為 18.42,5 年平均預期本益比為 18.98。

預期本益比

合理
5 年均值 P/E
18.98
目前P/E
18.42
高估
22.31
低估
15.65

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
13.79
目前EV/EBITDA
16.28
高估
15.91
低估
11.66

預期股價營收比

合理
5 年均值 P/S
2.42
目前P/S
2.39
高估
2.90
低估
1.95

Alphio AI 對 IQV 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%IQV

$150.52

情境價格

基

基準

基準 · 50%IQV

$139.87

情境價格

悲

悲觀

悲觀 · 25%IQV

$124.38

情境價格

持有 IQV 的大戶

H

Howard Capital Management, Inc.

+ 持有IQV

+17.25%

3個月報酬率

S

Singapore

+ 持有IQVTSM

+15.81%

3個月報酬率

E

Edmond de Rothschild Asset Management (France)

+ 持有IQV

+9.07%

3個月報酬率

C

Campbell & Company, LP

+ 持有IQV

+8.93%

3個月報酬率

L

Lakewood Capital Management, LP

+ 持有IQV

+7.00%

3個月報酬率

T

Trajan Wealth, L.L.C.

+ 持有IQV

+6.51%

3個月報酬率

事件時間軸

2026-10-13 (ET)

07:30:00

IQVIA and Veeva Expand Partnership

2026-10-07 (ET)

16:30:00

Iqvia Launches Life Science Models to Predict Clinical Trial Outcomes

16:30:00

Iqvia Launches Iqvia Explorer to Enhance Commercial Decision-Making

2026-09-15 (ET)

09:30:00

The Trade Desk Expands Integrations with Veeva and IQVIA

2026-09-09 (ET)

08:30:00

IQVIA Plans to Raise $2 Billion Through Senior Notes Offering

資訊

IQV 常見問題 —— 由 Alphio AI 解答

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易